MedElevator
Войти в исследования Asian Pacific journal of cancer prevention : APJCP · 2026
Ribosomal Proteins in Blood Exosomes as Markers of an Unfavorable Prognosis in Patients with Breast Cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Shefer Aleksei, Babaylova Elena, Yanshole Lyudmila, Grygoreva Alina, Svarovsky Dmitry, Graifer Dmitri, Malygin Alexey, Chernyshovа Alyona, Tamkovich Svetlana
Аннотация
INTRODUCTION: Exosomes, extracellular vesicles (EVs) 30-150 nm in diameter, are known to mediate intercellular communication by transferring bioactive molecules that can reprogram recipient cell phenotypes. Our analysis of 5-year survival data from breast cancer patients (BCPs) revealed that the poorest outcomes were exclusively associated with conserved signature of three ribosomal proteins (RPs) - MRPL52, RPL28, and RPL40 (UBA52) - that were completely absent in healthy females (HFs) and better-prognosis cases. Strikingly, all patients with this exosomal RP profile succumbed to metastatic relapse within the observation period.
METHODS: While RPs are known components of tumor-derived exosomes, their absence in EVs from normal cells suggests cancer-specific sorting mechanisms. To investigate this, we characterized exosomal RP cargo from three breast cancer cell lines (MCF-7, BT-474, BT-549), finding cell-type-specific RP patterns that differed from the clinical BC signature. Transfection of BT-549 cells with FLAG-tagged RPS3 (an aggressive cancer-associated RP) induced dramatic changes in exosomal RP composition, including the appearance of RPL28 - matching our clinical findings.
RESULTS: Bioinformatic analysis revealed that the RPs identified in BCP blood exosomes (MRPL52, RPL28, RPL40, RPS6) are associated with poor prognosis across multiple cancers and participate in key oncogenic pathways.
CONCLUSION: The concordance between our clinical and experimental data suggests that: (a) specific RPs are selectively packaged into exosomes under stress conditions; (b) this process may contribute to BC aggressiveness; (c) exosomal RP profiling could serve as a novel prognostic approach. These findings illuminate previously unrecognized roles of ribosomal components in cancer progression through EV-mediated communication.
METHODS: While RPs are known components of tumor-derived exosomes, their absence in EVs from normal cells suggests cancer-specific sorting mechanisms. To investigate this, we characterized exosomal RP cargo from three breast cancer cell lines (MCF-7, BT-474, BT-549), finding cell-type-specific RP patterns that differed from the clinical BC signature. Transfection of BT-549 cells with FLAG-tagged RPS3 (an aggressive cancer-associated RP) induced dramatic changes in exosomal RP composition, including the appearance of RPL28 - matching our clinical findings.
RESULTS: Bioinformatic analysis revealed that the RPs identified in BCP blood exosomes (MRPL52, RPL28, RPL40, RPS6) are associated with poor prognosis across multiple cancers and participate in key oncogenic pathways.
CONCLUSION: The concordance between our clinical and experimental data suggests that: (a) specific RPs are selectively packaged into exosomes under stress conditions; (b) this process may contribute to BC aggressiveness; (c) exosomal RP profiling could serve as a novel prognostic approach. These findings illuminate previously unrecognized roles of ribosomal components in cancer progression through EV-mediated communication.